First Wave BioPharma (FWBI) stock soars over 36% on upbeat trial data

November 30, 2021 09:11 AM PST | By Versha Jain
Follow us on Google News:


  • First Wave BioPharma, Inc. (NASDAQ: FWBI) jumps more than 36% in the premarket.
  • The biotech company announced on Tuesday that the data monitoring committee (DMA) recommended continuing enrollment for its Reservoir Phase 2 trials.
  • The trial data from the first 25 patients showed no safety issues. Furthermore, Part 2 of the study will involve 150 patients.

The First Wave BioPharma, Inc. (NASDAQ: FWBI) stock rose more than 36% in the premarket on Tuesday after announcing the data monitoring committee’s (DMA) decision to continue enrollment of its Reservoir Phase 2 trials for covid-related gastrointestinal infections.

The stock traded at US$2.58, up 36.51% from the previous close at about 8:30 am ET.

The independent committee reviewed the safety data from the trials on the first 25 patients. The data showed no safety issues. Furthermore, Part 2 of the study will involve 150 patients, the company said in a release. The announcement came at a time when the Omicron fear was looming, and that may have proved a boon for the covid drugmaker.

Also Read: Niantic IPO: Is the gaming company gearing up for public offer?

(First Wave BioPharma, Inc. (NASDAQ: FWBI)

Also Read: Nuvectis Pharma (NVCT) IPO: How to buy the stock?

Financials and stock performance

The Boca Raton, Florida-based FWBI is a clinical-stage biotechnology company. It develops non-systemic, targeted therapies for covid-related gastrointestinal diseases.

Its IPO came in October 2016. It has a market capitalization of US$23.55 million. 

The stock closed at US$1.94 on Nov 29. It traded in the range of US$26.30 to US$1.81 in the last 52 weeks. Analysts have set a one-year price target of US$20.0 for the stock.

Also Read: Polestar 5 sedan reveals production timeline, up against Tesla, Lucid

In the September quarter, 2021, the company incurred a net loss of US$30.4 million compared to US$5.3 million in the same period of 2020. However, the loss per share diluted reduced to US$(3.27) from the net loss per share of US$(4.72) a year ago.

Also Read: Who is Parag Agrawal?


The company expects the topline results from the trials to be available in 2022 by when the drug’s ability to remove the covid virus from the GI tract can be assessed. The NYSE Healthcare Index (NYP.ID) gave a 12.99% return YTD. In contrast, the FWBI stock fell by 80.52%.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies